effect and direct or secondary tissue injury, yet has not shown benefit in large pragmatic randomized controlled trials 4 . Less invasive strategies aim to achieve haematoma removal or reduction, with less associated brain tissue injury, and show promising outcomes in small studies 5 .
The minimally invasive surgery plus recombinant tissue plasminogen activator in intracerebral haemorrhage evacuation (MISTIE) trial assessed whether minimally invasive surgery (MIS) and rt-PA is safe and reduces clot burden, and obtained preliminary functional outcome data. All patients were managed in high-level care, with an intervention of a small craniotomy, image-guided catheter aspiration, thrombolysis with rt-PA, irrigation and drainage over several days. An initial rt-PA dose-finding stage led to stage two of the trial, in which 96 patients with spontaneous ICH ≥20 ml, "clinically stable" after 6 hours (clot expansion <5ml and no active bleeding on CT) were randomized to standard medical guideline-based care or MIS and rt-PA thrombolysis plus guideline-based care.
The primary outcome was "good outcome" on the adjusted dichotomized modified Rankin Scale (mRS) (0-3 vs 4-6) at 180 days. Primary safety outcomes were mortality, symptomatic bleeding, brain infections, and withdrawal of care. The population included 67% men, average age 61 years, with 66% basal ganglia and 34% lobar haematoma locations. The mean entry ICH size was 46ml, and median Glasgow Coma Scale 10. Safety outcomes did not differ between groups. At 180 days, the proportions with good recovery (mRS 0-3) were 33% in the MIS and rt-PA arm and 21% in the comparator medical arm. suggesting generalizability only to a minority of patients with ICH, although participants with deep and lobar ICH were included. Second, the intervention is complex, requiring adherence to a lengthy study intervention protocol with varied success measures in the trial, and most likely even greater variation if translated to real-world practice. Third, although apparently not increasing mortality, the study confirms that using rt-PA increases the risk of bleeding, albeit not at the expense of net long-term functional benefit -analogous to the accepted early ICH risk and improved long-term functional outcome associated with rt-PA in acute ischaemic stroke 6 . Finally, this small trial was not powered to show efficacy, leading to a wide range of estimated treatment effects.
It remains uncertain to what extent the apparent benefit of MIS is due to direct clot volume reduction through aspiration (limiting mass effect), or the use of rt-PA to continue removing blood products from the hematoma cavity (potentially reducing inflammation and other toxic secondary injury). Other techniques including clot endoscopic aspiration under direct guidance (without rt-PA) might therefore be of interest 7 . Although exploratory analyses suggest that better clot removal is associated with improved outcome, proving this hypothesis requires further trials. Thus, although MISTIE is a promising step forward, much larger trials in ICH patients recruited from both stroke and neurosurgical units are essential, to ensure that the results are not due to chance and can be replicated in current practice; until then the data are unlikely to directly influence current neurosurgical approaches. Nevertheless, if MISTIE and other minimally invasive techniques can be proven to produce meaningful functional benefit in patients with ICH, this could herald a new era in treating this most devastating of neurological emergencies.
